Clinical trial
Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced…
NCT00126230 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Terminated
Key facts
| NCT number | NCT00126230 |
|---|---|
| Title | Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer |
| Official title | A Prospective Phase II Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer Who Achieve a Response or a Stabilization to Docetaxel-Estramustine |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel and samarium |
| Enrollment | 55 |
| Start date | Jan 1, 2004 |
| First posted | Aug 3, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: